Overview

Testosterone Therapy in Castration Resistant Prostate Cancer

Status:
Active, not recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is an open-labeled, single-arm, interventional pilot study. It is being done to determine the feasibility of the administration of transdermal testosterone alternating with enzalutamide, as well as the safety and efficacy.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Cancer League of Colorado, Inc
National Cancer Institute (NCI)
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate